When Novo Nordisk reports earnings Wednesday morning, investors will be seeking reassurance that they haven’t overestimated the market for the new GLP-1 weight-loss medicines. When Novo’s competitor Eli Lilly reported its earnings last week,

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates appetite and digestion. The medications control blood sugar and help people eat less,

The Denmark-based drug maker Zealand Pharma said Tuesday that its experimental weight-loss drug could help patients lose pounds with fewer side effects than current anti-obesity medications on the market.

Drugs like Wegovy may trim your waistline but not medical costs, according to an analysis of U.S. health insurance claims shared with Reuters.

A mong the many newcomers to the business of weight-loss drugs is Hims & Hers, an American e-pharmacy better known for hawking remedies for erectile dysfunction and hair loss. Since May it has offered its own version of Wegovy,

Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a generic version of a Novo Nordisk diabetes and weight-loss drug as early as next year.

Telehealth company Hims & Hers said late Monday in an earnings update that it plans to launch a generic version of Novo Nordisk’s diabetes drug as soon as 2025. It reported strong quarterly earnings.